Chromosome 11: Genes, Functions, and Health Conditions

Chromosome 11 is one of the most gene-dense and disease-associated chromosomes in the human genome, carrying roughly 1,524 protein-coding genes across its 135 million base pairs. Despite being average in physical size, it is packed with genes that influence everything from how you smell to how your body handles insulin, and mutations along its length are linked to an unusually wide range of health conditions. Understanding what lives on this chromosome offers a surprisingly broad tour of human biology.

What Makes Chromosome 11 Stand Out

When the Human Genome Project’s sequencing teams published their detailed analysis of chromosome 11, they found an average density of about 11.6 genes per megabase, putting it among the most gene-rich chromosomes we carry.¹ That same analysis identified 765 pseudogenes and found that about one in four protein-coding genes on the chromosome overlaps with neighboring genes, a level of architectural complexity that helps explain why disruptions here tend to have outsized consequences.

One of the most striking features is the enormous concentration of olfactory receptor genes. Of the roughly 856 olfactory receptor genes scattered across the human genome, over 40% sit on chromosome 11, arranged in 28 clusters.¹ These receptors allow you to detect thousands of distinct odors. Most are functional, but many are pseudogenes, remnants of a time when smell played an even larger survival role for our ancestors. Researchers have investigated whether these dense olfactory receptor clusters make chromosome 11 structurally fragile, but a study examining translocation breakpoints found no statistical enrichment at olfactory receptor sites, suggesting that the clusters do not make the chromosome inherently breakage-prone.²

The Beta-Globin Gene Cluster and Sickle Cell Disease

Chromosome 11’s short arm hosts the beta-globin gene cluster, which encodes several of the protein chains that make up hemoglobin. This is the home of the HBB gene, where a single-letter change in the DNA produces sickle hemoglobin and causes sickle cell disease. But severity varies enormously from person to person, and the genetic neighborhood around HBB is a big part of the reason.

The pattern of common genetic variants flanking the sickle mutation, called a haplotype, differs depending on geographic ancestry, and these haplotypes correlate with clinical outcomes. Studies have identified several distinct haplotypes. In one framework, the Central African Republic haplotype is associated with the most severe disease, the Benin haplotype with intermediate severity, and the Senegal haplotype with milder symptoms.³ Much of this variation comes down to how much fetal hemoglobin a person continues to produce into adulthood, since fetal hemoglobin inhibits the sickling process. Haplotypes linked to higher fetal hemoglobin levels tend to produce milder disease.⁴

This understanding has had a direct impact on treatment. Gene-editing approaches using CRISPR-Cas9 now target the fetal hemoglobin genes (HBG1 and HBG2), which also sit on chromosome 11, to reactivate fetal hemoglobin production in adults with sickle cell disease. In an early clinical study, three participants who received CRISPR-edited stem cells achieved fetal hemoglobin levels between 19 and 27 percent of total hemoglobin, with fetal hemoglobin distributed across 70 to 88 percent of their red cells. Their sickle cell symptoms decreased over the follow-up period.⁵ Other CRISPR strategies aim to directly correct the sickle mutation in the HBB gene itself.⁶ Chromosome 11 has become one of the most active targets for gene therapy in all of medicine, largely because the biology of the beta-globin cluster is so well mapped.

Insulin and Blood Sugar Genes

The INS gene, which provides the blueprint for insulin, sits on chromosome 11p15. Mutations here are a recognized cause of neonatal diabetes, the rare form of diabetes that appears in the first months of life. The type of mutation matters. Dominant mutations tend to scramble the three-dimensional shape of the insulin protein, particularly by disrupting the bonds that hold it together. The misfolded protein accumulates inside beta cells, triggers a stress response, and eventually kills the cells.⁷ Recessive mutations, by contrast, tend to shut down insulin production entirely through mechanisms like gene deletion or disruption of the signals that stabilize the gene’s messenger RNA.⁸ The distinction has practical implications: understanding whether a baby’s neonatal diabetes comes from a dominant or recessive INS mutation helps clinicians predict whether remaining beta cells can be preserved.

Nearby on chromosome 11 are the KCNJ11 and ABCC8 genes, which encode the two subunits of a potassium channel that acts as the beta cell’s glucose sensor. When blood sugar rises, this channel closes, triggering insulin release. Activating mutations in these genes keep the channel stuck open, preventing insulin secretion and causing diabetes. Inactivating mutations do the opposite: they lock the channel shut, causing the beta cell to pour out insulin continuously, a condition called congenital hyperinsulinism that produces dangerously low blood sugar in newborns.⁹ These are the most common genetic causes of both neonatal diabetes and congenital hyperinsulinism, making this small stretch of chromosome 11 one of the most consequential regions for blood sugar regulation in the genome.¹⁰

The Apolipoprotein Cluster and Heart Disease Risk

At position 11q23, a cluster of apolipoprotein genes (APOA1, APOC3, APOA4, and APOA5) plays a central role in lipid metabolism. These genes encode proteins that help package and transport fats through the bloodstream. Variants in APOA5 and APOC3 in particular are strongly tied to plasma triglyceride levels.¹¹ Genome-wide association studies and Mendelian randomization analyses have linked variants in this cluster to broader lipid disorders, including elevated cholesterol and increased cardiovascular risk.¹²

What makes this cluster interesting beyond basic lipid biology is how tightly the genes are packed and co-regulated. Because they sit so close together, variants in one gene often travel with variants in the neighbors, making it tricky to pin down exactly which gene drives a particular association. Epigenetic modifications across the cluster add another layer of complexity. This region has become a focus for researchers trying to understand why some people develop dangerously high triglycerides while others with similar diets and lifestyles do not.

PAX6 and Eye Development

The PAX6 gene, located at 11p13, has been called the master regulator of the eye. It is essential for the correct formation of the iris, lens, cornea, retina, and fovea during embryonic development.¹³ Over 500 different mutations in PAX6 and its regulatory regions have been identified. Most of them reduce the amount of functional PAX6 protein by half, and that halving is enough to cause trouble.

The most recognized consequence is congenital aniridia, marked by partial or complete absence of the iris along with underdevelopment of the fovea and involuntary eye movements.¹⁴ The condition is inherited in an autosomal dominant pattern, meaning only one faulty copy is needed. People with aniridia often develop secondary complications over time, including glaucoma, cataracts, and corneal deterioration, because PAX6 continues to play a role in maintaining eye structures throughout life, not just during initial development.

WT1 and Wilms’ Tumor

Sitting close to PAX6 on the short arm of chromosome 11 is WT1, one of the first tumor suppressor genes ever identified. WT1 encodes a zinc-finger protein that acts as a transcription factor during kidney development. When both copies are knocked out, it predisposes children to Wilms’ tumor, a kidney cancer that typically appears before age five.¹⁵

The genetics follow the classic two-hit model of tumor suppression. In inherited cases, a child carries one defective WT1 copy in every cell; when the second copy is lost or damaged in a kidney cell, tumor growth begins. In sporadic cases, both hits occur in the same kidney cell by chance. One landmark study identified a 25-base-pair deletion within WT1 in a sporadic tumor, combined with loss of the entire other chromosome 11 copy through a separate event, neatly demonstrating how multiple genetic accidents converge.¹⁶ The proximity of WT1 and PAX6 is clinically relevant: large deletions at 11p13 can knock out both genes simultaneously, producing a condition called WAGR syndrome that combines Wilms’ tumor risk with aniridia and other features.

Imprinting and Opposite Growth Disorders

Chromosome 11p15.5 harbors one of the most important imprinted regions in the genome. Imprinting is the phenomenon where a gene’s activity depends on which parent it was inherited from: sometimes only the maternal copy is active, sometimes only the paternal one. When the imprinting marks at 11p15 go wrong, the results can be dramatic, and they go wrong in two opposite directions.

Beckwith-Wiedemann syndrome is an overgrowth condition. Children with it tend to be born large, with enlarged organs, and face an elevated risk of embryonal tumors including Wilms’ tumor. Russell-Silver syndrome is the mirror image: severe growth restriction before and after birth.¹⁷ Both trace back to disruptions in the same chromosomal neighborhood, but the disruptions push growth-regulating genes in opposite directions.¹⁸

A key player in this region is the IGF2 gene, which encodes a growth factor. Normally only the paternal copy of IGF2 is active, kept in check on the maternal side by the nearby H19 gene and its regulatory elements, including binding sites for an insulator protein called CTCF. Microdeletions that remove these CTCF binding sites on the maternal chromosome allow IGF2 to become active on both copies, producing excess growth factor. When the deletion is inherited from the mother, it has been associated with both Beckwith-Wiedemann syndrome and Wilms’ tumor.¹⁹ The fact that a deletion of just a couple of thousand base pairs can produce a recognizable clinical syndrome underscores how precisely this region is regulated.

Long QT Syndrome and the Heart’s Electrical Rhythm

The KCNQ1 gene, also at 11p15.5, encodes part of a potassium channel in heart muscle cells. This channel helps reset the heart’s electrical signal after each beat. Mutations in KCNQ1 are the most common cause of type 1 long QT syndrome, a condition where the heart takes too long to recharge between beats, potentially triggering dangerous arrhythmias. The gene spans about 400,000 base pairs across 19 exons, giving plenty of room for things to go wrong, and numerous distinct mutations have been found.²⁰

Some KCNQ1 mutations produce a “concealed” form of the condition. People with concealed long QT syndrome may have normal-looking heart tracings at rest, only to develop dangerous rhythm problems during exercise or emotional stress. Research into one such mutation, I235N, showed that the mutant channels functioned relatively normally under baseline conditions but failed to respond to the signaling pathway that the body uses to speed up the heart during physical activity. Simulations predicted that this insensitivity would primarily cause problems at slower heart rates during adrenaline stimulation, exactly the pattern seen in clinical cases.²¹ This kind of finding explains why some families carry the mutation for generations without anyone being diagnosed until a sudden cardiac event reveals it.

Mantle Cell Lymphoma and Cyclin D1

The CCND1 gene at 11q13 encodes cyclin D1, a protein that helps push cells through the growth cycle. In mantle cell lymphoma, a chromosomal rearrangement moves CCND1 next to an immunoglobulin gene, which is always switched on in immune cells. The result is massive overproduction of cyclin D1 and uncontrolled cell division. The classic translocation pairs chromosome 11 with chromosome 14, and it appears in virtually all cases of mantle cell lymphoma.²²

Rare variant translocations exist as well. In one documented case, CCND1 was rearranged with a different immunoglobulin gene on chromosome 22 rather than the usual partner on chromosome 14. The patient was initially misdiagnosed with chronic lymphocytic leukemia before the correct translocation and cyclin D1 overexpression were identified, leading to a revised diagnosis.²² These uncommon rearrangements are a diagnostic trap: because labs often screen only for the typical translocation, atypical cases can be missed if clinicians aren’t thinking broadly about CCND1 activation.

Jacobsen Syndrome and Large Deletions

When a sizable chunk of the long arm of chromosome 11 is lost, the result is Jacobsen syndrome. These terminal deletions remove multiple genes at once, producing a constellation of features including growth delays, intellectual disability, distinctive facial features, and a blood-clotting deficiency caused by low platelet counts. The thrombocytopenia can be severe enough to require platelet transfusions, and broader drops in blood cell counts are also possible. Because the deletion is large and variable in size, no two individuals have exactly the same set of missing genes, and clinical severity ranges widely.

BDNF, Tyrosinase, and Other Genes of Note

Beyond the headline conditions, chromosome 11 carries a number of other genes that have drawn research attention. The BDNF gene (brain-derived neurotrophic factor) at 11p14 is important for neuron growth and survival. In WAGR syndrome, where a deletion at 11p13 removes PAX6 and WT1, the deletion sometimes extends far enough to also take out one copy of BDNF. When that happens, the cognitive impact is measurably worse. In a study comparing individuals with WAGR syndrome who had lost one BDNF copy to those who had not, BDNF-haploinsufficient individuals scored about 20 IQ points lower on average and had meaningfully reduced adaptive behavior.²³ This finding has implications beyond WAGR, since BDNF is also under investigation in the context of depression, neurodegenerative disease, and cognitive aging.

The tyrosinase gene (TYR) was mapped to chromosome 11q14-q21. Tyrosinase is the enzyme responsible for producing melanin, the pigment in skin and eyes. Certain forms of oculocutaneous albinism result from mutations that disable this enzyme.²⁴ And the BACE1 gene at 11q23.3 encodes an enzyme involved in producing the amyloid-beta peptide that accumulates in Alzheimer’s disease, placing yet another major disease pathway on this chromosome.

Evolutionary Conservation Across Mammals

Chromosome 11’s gene content is not a human novelty. Comparative studies show that the block of genes carried on this chromosome has been remarkably stable across mammalian evolution, remaining largely intact in the common ancestor of primates and many other placental mammals.²⁵ In mice, the genes from human chromosome 11 are split across several different mouse chromosomes, but within each fragment the gene order is conserved. Six different human chromosome arms share stretches of matching genes with mouse chromosome 11, reflecting ancient chromosomal rearrangements that scrambled the packaging while preserving the gene neighborhoods themselves.²⁶

This conservation is more than a curiosity. It means that mouse models carrying mutations in these shared gene regions can closely mimic human diseases, which is exactly why mouse studies have been so productive for conditions like sickle cell disease, Wilms’ tumor, and insulin disorders. The genes that nature has kept together on chromosome 11 for tens of millions of years tend to be the ones where mutations have the biggest biological consequences, which goes a long way toward explaining why this average-sized chromosome punches so far above its weight in human disease.